Overview

This trial is active, not recruiting.

Condition breast cancer
Treatment tamoxifen
Sponsor King Faisal Specialist Hospital & Research Center
Start date September 2007
End date September 2020
Trial size 2000 participants
Trial identifier NCT00538330, RAC #93-107

Summary

Post operative adjuvant chemotherapy followed by adjuvant Tamoxifen vs nil for patients with operable breast cancer

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose health services research

Primary Outcomes

Measure
safety
time frame: 10 years

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patients with operable breast cancer

Additional Information

Principal investigator Adnan Ezzat, MD
Trial information was received from ClinicalTrials.gov and was last updated in December 2011.
Information provided to ClinicalTrials.gov by King Faisal Specialist Hospital & Research Center.